AC	adrenal crisis;
ACTH	adrenocorticotropic hormone;
ADH	antidiuretic hormone;
AE	adverse event;
AGHD	adults with growth hormone deficiency;
AI	adrenal insufficiency;
AVP	arginine vasopressin;
BSA	body surface area;
BW	body weight;
CBG	corticosteroid-binding globulin;
CDI	central diabetes insipidus;
CSHI	continuous subcutaneous hydrocortisone infusion;
CTLA-4	cytotoxic T-lymphocyte antigen-4;
DDAVP	1-desamino-8-D-arginine-vasopressin or desmopressin;
DHEA	dehydroepiandrosterone;
DHEAS	dehydroepiandrosterone sulfate;
DI	diabetes insipidus;
DM	diabetes mellitus;
E2	oestradiol;
ICI	immune checkpoint inhibitors;
IGF	insulin-like growth factor;
IHD	isolated deficiency;
IM	intramuscularly;
IV	intravenously;
FSH	follicle stimulating hormone;
fT4	free T4;
GC	glucocorticoid;
GH	growth hormone;
GHD	growth hormone deficiency;
GnRH	gonadotropin-releasing hormone;
HC	hydrocortisone;
HCDC	hydrocortisone day-curve;
HCeq	equivalent hydrocortisone dose;
hCG	human chorionic gonadotropin;
hMG	human menopausal gonadotropin;
HRT	hormonal replacement therapy;
LH	Luteinizing Hormone;
L-T4	levothyroxine;
MDT	multidisciplinary team;
MPHD	multiple pituitary hormone deficiency;
MRHC	once-daily modified-release hydrocortisone;
NFPA	non-functioning pituitary adenoma;
PAI	primary adrenal insufficiency;
PD-1	programmed cell-death-1;
PD-L1	programmed cell-death-ligand 1 (PD-L1);
PHG	primary hypogonadism;
PitAp	pituitary apoplexy;
PRL	prolactin;
PSA	prostate specific antigen;
QoL	quality of life;
r-hGH	recombinant human growth hormone;
SAI	central or secondary adrenal insufficiency;
SC	subcutaneously;
SDS	standard deviation score;
SHG	secondary hypogonadism;
SHT	secondary hypothyroidism;
TBG	thyroid-binding globulin;
TSH	thyroid-stimulating hormone;
UFC	urinary free cortisol;
ULN	upper limit of normal;
11β-HSD1	enzyme 11β-hydroxysteroid dehydrogenase